Nintedanib 150 mg Capsule : Uses, Side Effects, Dosage & Price in India

Introduction

NINTEDONE 150 Capsule is an advanced prescription medication developed for patients suffering from serious and progressive lung diseases. The active ingredient, Nintedanib 150 mg, is a targeted antifibrotic therapy used to manage Idiopathic Pulmonary Fibrosis (IPF) and other interstitial lung diseases characterized by chronic fibrosis. Manufactured with precision and care, NINTEDONE 150 is designed to slow the progression of lung tissue scarring, thereby preserving lung function and improving patient quality of life.

What is NINTEDONE 150 (Nintedanib 150 mg Capsule)?

NINTEDONE 150 is a prescription medication that contains Nintedanib 150 mg, a tyrosine kinase inhibitor used to treat idiopathic pulmonary fibrosis (IPF), systemic sclerosis-associated interstitial lung disease (SSc-ILD), and chronic fibrosing interstitial lung diseases with a progressive phenotype. It helps slow down the decline in lung function by blocking multiple pathways that lead to lung tissue scarring.

Extended Benefits of Nintedanib 150 mg

• May help reduce the frequency of acute exacerbations in ILD patients

• Slows down the decline in Forced Vital Capacity (FVC)

• Improves long-term respiratory outcomes when initiated early in disease course

• May be used as part of combination therapy in consultation with pulmonologists

Who Should Take Nintedanib 150 mg?

• Adults diagnosed with Idiopathic Pulmonary Fibrosis (IPF)

• Patients with SSc-ILD or other progressive fibrosing ILDs

• Those who have experienced a rapid decline in lung function over 6–12 months

• Patients not responding adequately to steroids or immunosuppressive therapy

Uses of Nintedanib 150 mg Capsule

• Treatment of Idiopathic Pulmonary Fibrosis (IPF)

• Management of Systemic Sclerosis-Associated Interstitial Lung Disease (SSc-ILD)

• Treatment of chronic fibrosing ILDs with a progressive phenotype

Mechanism of Action of Nintedanib

Nintedanib is a multi-targeted tyrosine kinase inhibitor that blocks receptors such as PDGFR, FGFR, and VEGFR, involved in the fibrotic process. By inhibiting these pathways, Nintedanib reduces fibroblast proliferation and extracellular matrix deposition, thereby slowing disease progression.

Pharmacokinetics of Nintedanib

• Absorption: Peak plasma concentrations occur 2–4 hours post-dose

• Bioavailability: Approx. 4.7% (increased with food)

• Half-life: 9.5 hours

• Metabolism: Primarily by esterases and CYP3A4

• Excretion: Predominantly via feces

Dosage of Nintedanib 150 mg Capsule

• Usual dose: One Nintedanib 150 mg capsule twice daily, approximately 12 hours apart

• Should be taken with food to reduce gastrointestinal side effects

• Dose adjustments may be needed in patients with liver impairment or severe adverse reactions

Side Effects of Nintedanib 150 mg

Common Side Effects:

• Diarrhea

• Nausea and vomiting

• Abdominal pain

• Decreased appetite

• Weight loss

Serious Side Effects:

• Liver enzyme elevation

• Gastrointestinal perforation

• Bleeding risk

• Arterial thromboembolic events

• Interstitial lung disease

Monitoring and Laboratory Testing

• Liver Function Tests (ALT, AST) every 1–2 months initially

• CBC and coagulation profile in bleeding risk patients

• Monitoring for signs of GI perforation (acute abdomen)

• Pulmonary function tests every 3–6 months to track efficacy

Precautions Before Using Nintedanib 150 mg

• Use cautiously in patients with liver disorders

• Monitor liver function tests (LFTs) regularly

• Not recommended during pregnancy and breastfeeding

• Patients with bleeding risks or on anticoagulants should consult their doctor

• Inform the doctor about all ongoing medications and allergies

Drug Interactions with Nintedanib

• P-gp inhibitors (e.g., ketoconazole, erythromycin) can increase Nintedanib levels

• P-gp inducers (e.g., rifampicin, carbamazepine) may decrease its effectiveness

• Use with anticoagulants or antiplatelet agents may increase bleeding risk

• Avoid concomitant use with strong CYP3A4 inducers

Lifestyle and Dietary Recommendations

• Stay hydrated to help manage diarrhea

• Eat smaller, more frequent meals to reduce nausea

• Avoid alcohol to minimize liver strain

• Quit smoking to improve overall lung function

Price & Availability

• Generic Nintedanib 150 mg capsules are available under the brand name NINTEDONE 150

• Pricing may vary depending on region, packaging, and distributor

• For best offers and genuine product availability, prefer certified pharmaceutical providers like Steris Healthcare Pvt. Ltd.

Frequently Asked Questions (FAQs)

Q1. How long can Nintedanib 150 mg be taken?
A: Treatment duration is determined by your doctor based on disease severity and tolerance. Many patients use it for extended periods under monitoring.

Q2. Can I stop Nintedanib 150 mg if I feel better?
A: No. Do not stop without consulting your doctor. Stopping suddenly may allow disease progression.

Q3. Is Nintedanib a steroid?
A: No, it is not a steroid. Nintedanib is a tyrosine kinase inhibitor with antifibrotic properties.

Q4. Can Nintedanib be used for COVID-19-related lung fibrosis?
A: In some cases, doctors may consider antifibrotics like Nintedanib for post-COVID fibrosis. However, its use should be strictly under specialist guidance.

Q5. What should I do if I miss a dose?
A: Skip the missed dose and continue with your regular schedule. Do not double the dose.

Q6. How soon can I expect results from Nintedanib 150 mg?
A: Results vary, but lung function stabilization may be noticeable within 3–6 months.

Q7. Can this medicine be used in elderly patients?
A: Yes, but with caution. Elderly patients should be monitored closely for side effects.

Why Choose Steris Healthcare Pvt. Ltd.?

• WHO-GMP and ISO certified manufacturing

• High-quality, affordable formulations

• Trusted across India for excellence in chronic disease care

• Prompt delivery and strong customer support

• Strict quality control and international standard packaging

Conclusion

NINTEDONE 150 Capsule, powered with Nintedanib 150 mg, is a scientifically proven therapy for managing progressive and fibrotic lung conditions like Idiopathic Pulmonary Fibrosis (IPF) and SSc-ILD. With regular monitoring, proper dosage, and guidance from a healthcare professional, it can significantly improve the prognosis and slow disease advancement.

Choose Steris Healthcare Pvt. Ltd. for access to reliable, effective, and affordable respiratory care products across India.